Search
Clinician Ordering Portal
On Demand Education
Recent developments in prognostic and predictive testing in uveal melanoma.
May 2014
Curr Opin in Ophthalmol 2014;25(3):234-9.
Instrument gauge and type in uveal melanoma fine needle biopsy: implications for diagnostic yield and molecular prognostication.
Aug 2020
Am J Ophthalmol 2020; online ahead of print.
Collaborative Ocular Oncology Group Report Number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma.
Aug 2012
Ophthalmology 2012;119: 1596-1603.
An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.
Jul 2010
J Mol Diagn 2010;12(4):461-8.
Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens.
Nov 2006
J Mol Diagn 2006;8:567-73.
Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics.
Diagn Pathol 2017;12(1):59.
Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling.
Mar 2020
Melanoma Manag 2020;7(1):MMT37.
PRAME as an independent biomarker for metastasis in uveal melanoma.
Mar 2016
Clin Cancer Res 2016;22(5):1234-42.
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.
Apr 2011
J Med Genet 2011;48:856-9.
Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes.
Jul 2016
JAMA Ophthalmol 2016;134:728-33.
Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Aug 2014
Invest Ophthalmol Vis Sci 2014;55:5160-7.